Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Corvus Pharmaceuticals (CRVS) Operating Expenses (2016 - 2026)

Corvus Pharmaceuticals' Operating Expenses history spans 12 years, with the latest figure at $14.9 million for Q1 2026.

  • Quarterly Operating Expenses rose 49.94% to $14.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $47.9 million through Mar 2026, up 53.53% year-over-year, with the annual reading at $43.0 million for FY2025, 55.99% up from the prior year.
  • Operating Expenses came in at $14.9 million for Q1 2026, up from $12.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $14.9 million in Q1 2026 to a low of $5.6 million in Q3 2023.
  • The 5-year median for Operating Expenses is $7.3 million (2024), against an average of $8.3 million.
  • Year-over-year, Operating Expenses tumbled 55.42% in 2023 and then surged 72.87% in 2025.
  • Corvus Pharmaceuticals' Operating Expenses stood at $5.7 million in 2022, then fell by 0.26% to $5.7 million in 2023, then soared by 43.43% to $8.1 million in 2024, then soared by 50.73% to $12.2 million in 2025, then grew by 21.77% to $14.9 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Operating Expenses are $14.9 million (Q1 2026), $12.2 million (Q4 2025), and $10.6 million (Q3 2025).